We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Alligator Bioscience Ab | LSE:0RK9 | London | Ordinary Share | SE0000767188 | ALLIGATOR BIOSCIENCE ORD SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 23.00 | 5,000 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 59.27M | -248.59M | -0.3778 | -60.88 | 15.13B |
STOCKHOLM, Feb. 11, 2022 /PRNewswire/ -- OPTIMIZE-1 Phase II - On Track and Moving Forward
"During the fourth quarter 2021, Alligator reached several key milestones in our pre-clinical, clinical, and partnered programs. Our priorities continue to be shaped by the rising need for cancer drug therapies that are safer and more effective."
Søren Bregenholt
CEO Alligator Bioscience AB (publ)
Significant Events: October - December 2021
FINANCIAL SUMMARY
October-December 2021
January-December 2021
The full report is attached as PDF available on the company's website: https://alligatorbioscience.se/en/investors/financial-reports/
Conference call/webcast
Alligator will host a conference call today, February 11, 2022, at 3:30 p.m. CEST for investors, analysts and media, where CEO Søren Bregenholt and CFO Marie Svensson will present and comment on the Interim Report. The conference call will be held in English.
The conference call will be broadcast live on the web and can be accessed via the link:
Alligator Bioscience, Audiocast with teleconference, Q4, 2021 | Financial Hearings
Dial-in numbers:
SE: +46850558357
UK: +443333009271
US: +16467224957
For further information, please contact:
Julie Silber, Investor Relations
Phone: +46 46-540 82 23
E-mail: jur@alligatorbioscience.com
This information is such information as Alligator Bioscience AB (publ) is obliged to make public pursuant to the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 a.m. CEST on February 11, 2022.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, with MacroGenics Inc. and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator Bioscience's shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.
For more information, please visit http://www.alligatorbioscience.com.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-ab--year-end-report-january-december-2021,c3504379
The following files are available for download:
https://mb.cision.com/Main/12681/3504379/1533438.pdf | Alligator Bioscience AB: Year End report Januaryâ€"December 2021 (PDF) |
https://mb.cision.com/Public/12681/3504379/931db7b3e5a07579.pdf | Press release (PDF) |
Copyright 2022 PR Newswire
1 Year Alligator Bioscience Ab Chart |
1 Month Alligator Bioscience Ab Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions